{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008301","form_type":"8-K","ticker":"LNSR","cik":"0001320350","company_name":"LENSAR, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.377999+00:00","generated_at":"2026-06-18T00:13:29.390869+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"LENSAR Q4 2022 revenue $10.2M (-9% YoY); net loss narrows to $2.5M from $3.9M","bullets":["Q4 2022 total revenue $10.2M, down 9% from $11.2M in Q4 2021 due to lower South Korea procedure revenue.","Net loss Q4 2022: $2.5M ($0.24 per share) vs $3.9M ($0.41) in Q4 2021; Adjusted EBITDA improved to ($0.065M) from ($1.6M).","Installed ten ALLY Adaptive Cataract Treatment Systems in 2022; contracts signed for six more systems, installations expected H1 2023.","SG&A expenses rose 24% to $7.2M, driven by ALLY promotion; R&D fell 53% to $1.6M as ALLY development costs normalized.","CEO reports positive surgeon feedback: ALLY cuts 1-1.5 hours from surgical day, supports faster case volume."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008301","json":"https://secwatch.observer/filing/0000950170-23-008301.json","markdown":"https://secwatch.observer/filing/0000950170-23-008301.md","text":"https://secwatch.observer/filing/0000950170-23-008301.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/0000950170-23-008301-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/lnsr-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:13:29.390869+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b164845c25c8a1b7e449d89271b3ba019d6dc997","claim":"LENSAR, Inc. reported the quarter ended December 31, 2022 results: revenue $10.2 million, net income $2.5 million, or ($0.24) per share, EPS ($0.24) per share.","evidence_excerpt":"and so accurate that I have added at least 3 to 4 cases onto my surgery days.\" Fourth Quarter 2022 Financial Results Total revenue for the quarter ended December 31, 2022 was $10.2 million, a decrease of $1.0 million, or 9%, compared to total revenue of $11.2 million for the quarter ended December 31, 2021. The decrease from the fourth quarter of 2021 was primarily","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1320350/000095017023008301/0000950170-23-008301-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended December 31, 2022"},{"label":"Revenue","value":"$10.2 million"},{"label":"Net income","value":"$2.5 million, or ($0.24) per share"},{"label":"EPS","value":"($0.24) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}